Leila Alland - Aug 9, 2021 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)

Role
Chief Medical Officer
Signature
/s/ Winston Kung, by power of attorney
Stock symbol
PMVP
Transactions as of
Aug 9, 2021
Transactions value $
-$136,602
Form type
4
Date filed
8/10/2021, 06:14 PM
Previous filing
Jul 8, 2021
Next filing
Sep 8, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PMVP Common Stock Options Exercise $15.6K +4K $3.90 4K Aug 9, 2021 Direct
transaction PMVP Common Stock Sale -$77.1K -2.2K -54.95% $35.06 1.8K Aug 9, 2021 Direct F1, F2
transaction PMVP Common Stock Sale -$66.9K -2.05K -90.15% $32.66 224 Aug 9, 2021 Direct F1, F3
transaction PMVP Common Stock Sale -$8.22K -224 -100% $36.69 0 Aug 9, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PMVP Employee Stock Option (right to buy) Options Exercise $0 -4K -1.11% $0.00 358K Aug 9, 2021 Common Stock 4K $3.90 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.575 to $35.39, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.605 to $36.50, inclusive.
F4 One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.